Acadia pharmaceuticals provides business and pipeline updates at 43rd annual j.p. morgan healthcare conference

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced multiple business updates and progress on the company's cns and rare disease drug candidates, which will be discussed today during a presentation by catherine owen adams, chief executive officer, at the 43rd annual j.p. morgan healthcare conference in san francisco, ca. “2025 is shaping up to be an exciting year as we build on the success of our two growing brands, nuplazid and daybue, which together are proj.
ACAD Ratings Summary
ACAD Quant Ranking